{"organizations": [], "uuid": "a0e0442ce4ecddd20da1e1d6ab7886f5e66dbbae", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-biolinerx-announces-notice-of-allo/brief-biolinerx-announces-notice-of-allowance-from-uspto-for-patent-covering-immunotherapy-for-treating-solid-tumors-idUSFWN1R80H8", "country": "US", "domain_rank": 408, "title": "BRIEF-BioLineRx Announces Notice of Allowance From USPTO for Patent Covering Immunotherapy for Treating Solid Tumors", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-26T14:27:00.000+03:00", "replies_count": 0, "uuid": "a0e0442ce4ecddd20da1e1d6ab7886f5e66dbbae"}, "author": "", "url": "https://www.reuters.com/article/brief-biolinerx-announces-notice-of-allo/brief-biolinerx-announces-notice-of-allowance-from-uspto-for-patent-covering-immunotherapy-for-treating-solid-tumors-idUSFWN1R80H8", "ord_in_thread": 0, "title": "BRIEF-BioLineRx Announces Notice of Allowance From USPTO for Patent Covering Immunotherapy for Treating Solid Tumors", "locations": [], "entities": {"persons": [], "locations": [{"name": "uspto", "sentiment": "none"}, {"name": "europe", "sentiment": "none"}, {"name": "australia", "sentiment": "none"}, {"name": "canada", "sentiment": "none"}, {"name": "china", "sentiment": "none"}, {"name": "japan", "sentiment": "none"}], "organizations": [{"name": "treating solid tumors reuters staff", "sentiment": "none"}, {"name": "min read   bioline rx ltd", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 27 AM / Updated 13 minutes ago BRIEF-BioLineRx Announces Notice of Allowance From USPTO for Patent Covering Immunotherapy for Treating Solid Tumors Reuters Staff 1 Min Read   Bioline Rx Ltd: * BIOLINERX ANNOUNCES NOTICE OF ALLOWANCE FROM USPTO FOR PATENT COVERING AGI-134 - A NOVEL IMMUNOTHERAPY FOR TREATING SOLID TUMORS * BIOLINE RX LTD - ‍THIS PATENT, WHEN ISSUED, WILL BE VALID UNTIL MAY 2035 WITH A POSSIBILITY OF UP TO FIVE YEARS PATENT TERM EXTENSION​ * BIOLINE RX LTD - ‍ADDITIONAL CORRESPONDING PATENT APPLICATIONS FOR AGI-134 ARE PENDING IN EUROPE, JAPAN, CHINA, CANADA, AUSTRALIA AND ISRAEL​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-26T14:27:00.000+03:00", "crawled": "2018-03-26T14:42:57.009+03:00", "highlightTitle": ""}